Dacarbazine

Dacarbazine

SCHEMBL5560

CN(C)/N=N/c1[nH]cnc1C(N)=O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 3/20 0.59
LMNA P02545 2/20 0.59
TSHR P16473 2/20 0.59
KDM4E B2RXH2 2/20 0.59
ALDH1A1 P00352 2/20 0.59
MMP9 P14780 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
MAPT P10636 2/20 0.38
PKM P14618 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GDA Q9Y2T3 1/20 0.36
PARP1 P09874 1/20 0.31
CYP2C19 P33261 2/20 0.31
CYP1A2 P05177 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CYP2D6 P10635 1/20 0.31
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dacarbazine SCHEMBL12591753 1.00 PAX8 (0.59) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL1586950 1.00 PAX8 (0.59) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL6372 1.00 PAX8 (0.59) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL28074492 0.98 PAX8 (0.57) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL29042921 0.98 PAX8 (0.57) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL28074490 0.98 PAX8 (0.57) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL28090781 0.98 PAX8 (0.57) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL28242658 0.98 PAX8 (0.57) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL3957404 0.98 PAX8 (0.57) PAX8LMNATSHRKDM4EALDH1A1
Dacarbazine SCHEMBL28090782 0.98 PAX8 (0.57) PAX8LMNATSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 142554 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
CN-116209439-B Cereblon protein modulators Saint Jude Children's Research Hospital Ltd. (US) 2026-05-26 CN claimed
CN-122074048-A Methods of treating cancer 诺华股份有限公司 2026-05-22 CN claimed
WO-2026107377-A1 PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL KARANICOLAS JOHN (US) 2026-05-21 WO claimed
US-20260137650-A1 MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) 11949098 CANADA INC (CA) 2026-05-21 US claimed
US-20260139071-A1 Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses JANSSEN BIOTECH INC (US) 2026-05-21 US claimed
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE SK BIOPHARMACEUTICALS CO LTD (KR) 2026-05-21 US claimed
US-20260137794-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF SYSTIMMUNE INC (US) 2026-05-21 US claimed
WO-2026102563-A1 DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF 深圳湾实验室坪山生物医药研发转化中心 2026-05-21 WO claimed
WO-2026105121-A1 ANTICANCER FORMULATIONS AND USES THEREOF INTRAGEL THERAPEUTICS LTD. (IL) 2026-05-21 WO claimed
US-4772459-A N-(PYRROLIDINYL-OR PIPERIDINYLALKYL) ETHER-SUBSTITUTED BENZAMIDES ERBAMONT, INC. (US) 1988-09-20 US claimed
WO-1988001866-A1 METHOD FOR CONTROLLING EMESIS CAUSED BY CHEMOTHERAPEUTIC AGENTS AND ANTIEMETIC AGENTS USEFUL THEREIN ADRIA LABORATORIES, INC. (US) 1988-03-24 WO claimed
US-4722834-A Method of using 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide-N-oxides to control emesis caused by anticancer drugs A. H. ROBINS COMPANY, INCORPORATED (US) 1988-02-02 US claimed
EP-0240180-A1 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs SYNTHELABO (FR) 1987-10-07 EP claimed
EP-0237281-A1 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamide-N-oxides in the control of emesis caused by anticancer drugs SYNTHELABO (FR) 1987-09-16 EP claimed
EP-0227593-A1 Use of chelating agents THE HOSPITAL FOR SICK CHILDREN (CA) 1987-07-01 EP claimed
EP-0189849-A2 Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans Sloan-Kettering Institute For Cancer Research (US) 1986-08-06 EP claimed
EP-0120907-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY Aston Molecules Limited (GB) 1984-10-10 EP claimed
WO-1984001506-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY UNIV BIRMINGHAM (GB) 1984-04-26 WO claimed
EP-0010964-A1 Ravidomycin, process of preparation and pharmaceutical compositions containing same AYERST, MCKENNA AND HARRISON INC. (CA) 1980-05-14 EP claimed